|Title:||Minimally differentiated acute myeloid leukemia in Taiwan: Predominantly occurs in children less than 3 years and adults between 51 and 70 years||Authors:||SHANG-YI HUANG
|Issue Date:||1999||Publisher:||Nature Publishing Group||Journal Volume:||13||Journal Issue:||10||Start page/Pages:||1506-1512||Source:||Leukemia||Abstract:||
Acute myeloid leukemia (AML) with minimal differentiation was usually referred to as acute undifferentiated leukemia in the past. With the help of immunophenotyping, this subtype of leukemia was shown to express myeloid antigens on the blasts and was designated AML-MO by FAB Cooperative Study Group in 1991. Among the 423 consecutive newly diagnosed de novo AML at our institution, 12 (2.8%) were of MO subtype. The proportion of MO in AML was higher in children than in adults (8.2% vs 1.7%). Four other MO patients referred from outside hospitals for immunophenotyping were also included in this study. There were two peaks in age distribution of these 16 patients: less than 3 years and between 51 and 70 years, respectively. Organomegaly was more common in patients with AML-MO than in those with other subtypes (56.3% vs 29.2%, P = 0.025). The former patients had higher incidences of CD7 and CD34 expression on the leukemic cells than the latter ones (50% vs 16.9%, P = 0.003 and 69.2% vs 37.9%, P = 0.019, respectively). The patients with AML-MO showed more frequent clonal chromosomal abnormalities in the leukemic cells than other AML patients (83.3% vs 53.9%, P = 0.039); the same is also true for complex cytogenetic aberrations (50% vs 11.4%, P = 0.004). Adults with AML-MO showed a lower complete remission (CR) rate and significantly poorer survival than those with non MO-AML. However there was no significant difference in outcome between the two groups of pediatric patients. In conclusion, AML-MO is a unique subtype of leukemia that has distinct age distribution and shows different clinical and biological characteristics from other AML. Adult patients have poor prognosis. Whether pediatric patients had better outcome than adults needs to be clarified in further studies.
|ISSN:||0887-6924||DOI:||10.1038/sj.leu.2401521||SDG/Keyword:||anthracycline; CD34 antigen; CD7 antigen; cyclophosphamide; cytarabine; epirubicin; etoposide; mercaptopurine; methotrexate; tioguanine; acute granulocytic leukemia; adolescent; adult; aged; antigen expression; article; blast cell; cancer classification; cancer survival; child; cytogenetics; differentiation; female; human; human cell; immunophenotyping; infant; intravenous drug administration; leukemia remission; major clinical study; male; oral drug administration; priority journal; prognosis; Taiwan
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.